Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Laura Sue Grosmaire"'
Autor:
Kerry L. Cox, Robert J. Oldham, Adam Palazzo, Florian Limani, Michael J. E. Marshall, Christian R. Frey, Christian Klein, Randy Jones, Matthew J. Carter, Sylvia Herter, Marina Bacac, Mark S. Cragg, Anna H. Turaj, Laura Sue Grosmaire, Pablo Umana, Stacey Tannheimer
Publikováno v:
The Journal of Immunology Author Choice
Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonst
Autor:
Lynne H. Wu, Hans D. Ochs, Jeffrey A. Ledbetter, Randolph J. Noelle, Shigeaki Nonoyama, Laura Sue Grosmaire, Diane Hollenbaugh, Harry Hill, Alejandro Aruffo
Publikováno v:
Journal of Clinical Investigation. 94:616-622
The molecular origin of X-linked hyper IgM syndrome has recently been identified as a defect in the ligand of CD40, gp39, a protein expressed on the surface of activated T cells. The availability of detailed pedigrees for three families with affected
Publikováno v:
Proceedings of the National Academy of Sciences. 90:7099-7103
One of the beta 2-integrins found on hematopoietic cells is lymphocyte function-associated antigen 1 (LFA-1), a lymphocyte/myeloid cell-specific receptor that binds to members of the intercellular adhesion molecule (ICAM) family on antigen-presenting
Autor:
Ronald E. Stenkamp, Robert L. Roberts, Michael G. Neubauer, Randolph J. Noelle, Shigeaki Nonoyama, Diane Hollenbaugh, Mary Farrington, Uta Francke, Hans D. Ochs, Jeffrey A. Ledbetter, Athena Milatovich, Laura Sue Grosmaire, Jürgen Bajorath, Xu Li, Alejandro Aruffo
Publikováno v:
Cell. 72:291-300
The prominent role of the CD40 receptor in B cell responses led us to investigate the role of the gp39-CD40 interaction in a group of primary immunodeficient patients with defective antibody production. Here we report that patients with hyper-IgM syn
Autor:
Martha Hayden-Ledbetter, Erik Stephen Espling, Robert Bader, Sonya Slater, Philip Tan, Christy Anne Nilsson, Cheryl Bradley, Laura Sue Grosmaire, Alan F. Wahl, Chuck G. Cerveny, Alexander Simon, Dauphine S. Barone, William Brady, Peter A. Thompson, Jeffrey A. Ledbetter
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(8)
Purpose: CD20-directed therapy with rituximab is effective in many patients with malignant lymphoma or follicular lymphoma. However, relapse frequently occurs within 1 year, and patients become increasingly refractory to retreatment. Our purpose was
Autor:
Paul J. Martin, Niels Ødum, Jeffrey A. Ledbetter, Gary L. Schieven, Nancy A. Norris, Laura Sue Grosmaire, John A. Hansen
Publikováno v:
Human Immunology. 32:85-94
Recently, it was shown that HLA class II molecules on B cells and activated human T cells can transmit signals involving tyrosine phosphorylation of specific proteins, activation of the inositol phospholipid pathway, and release of cytosolic free Ca2
Autor:
Jeffrey A. Ledbetter, Peter S. Linsley, Laura Sue Grosmaire, Nitin K. Damle, William E. Brady, Mark Urnes
Publikováno v:
The Journal of Experimental Medicine
Functional interactions between T and B lymphocytes are necessary for optimal activation of an immune response. Recently, the T lymphocyte receptor CD28 was shown to bind the B7 counter-receptor on activated B lymphocytes, and subsequently to costimu
Publikováno v:
Biochemical Society Transactions. 19:269-272
Autor:
Peter S. Linsley, Laura Sue Grosmaire, Jeffrey A. Ledbetter, Nitin K. Damle, Alejandro Aruffo, William E. Brady
Publikováno v:
The Journal of Experimental Medicine
A successful immune response requires intercellular contact between T and B lymphocytes. We recently showed that CD28, a T cell surface protein that regulates an activation pathway, could mediate intercellular adhesion with activated B cells by inter
Autor:
Stacey Tannheimer, Jia Liu, Pablo Umana, Christophe Quéva, Laura Sue Grosmaire, Sylvia Herter, Stefan Pflanz, Christian R. Frey, Christian Klein, Adam Palazzo, Marina Bacac
Publikováno v:
Blood. 124:3342-3342
Introduction: Idelalisib is a highly selective oral inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) that is hyperactive in many B-cell malignancies and is critical for the activation, proliferation, survival and trafficking of B lymphocytes